LOGIN
Short-term benefits of tamoxifen in Dupuytren patients with a predisposition to fibrosis
July 2014
Short-term benefits of tamoxifen in Dupuytren patients with a predisposition to fibrosis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial
J Bone Joint Surg Am. 2014 Apr 16;96(8):655-62Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
30 patients suffering from Dupuytren disease, with a predisposition toward fibrosis, were randomized to evaluate the efficacy of tamoxifen against a placebo, following subtotal fasciectomy. Patients were regularly assessed over 2 years to evaluate improvements of total passive extension deficit, and satisfaction as determined by the visual analogue scale (VAS).The evidence presented in this trial ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.